HCW Biologics Inc (HCWB)

Form 8-K - Current report

Form 8-K - Current report

HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter

MIRAMAR, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”...

Form 8-K - Current report

HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026

Company completed 28 consecutive trading days above $1.00 per share on June 25, 2026 Reverse stock split...

Form EFFECT - Notice of Effectiveness

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form 8-K - Current report

HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata

Potentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T...

Form 8-K - Current report

Form D - Notice of Exempt Offering of Securities

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities